Older Ethan A, Zhang Jian, Ferris Zachary E, Xue Dan, Zhong Zheng, Mitchell Mary K, Madden Michael, Wang Yuzhen, Chen Hexin, Nagarkatti Prakash, Nagarkatti Mitzi, Fan Daping, Ellermann Melissa, Li Yong-Xin, Li Jie
bioRxiv. 2023 May 2:2023.03.16.533047. doi: 10.1101/2023.03.16.533047.
The trillions of microorganisms inhabiting the human gut are intricately linked to human health. At the species abundance level, correlational studies have connected specific bacterial taxa to various diseases. While the abundances of these bacteria in the gut serve as good indicators for disease progression, understanding the functional metabolites they produce is critical to decipher how these microbes influence human health. Here, we report a unique biosynthetic enzyme-guided disease correlation approach to uncover microbial functional metabolites as potential molecular mechanisms in human health. We directly connect the expression of gut microbial sulfonolipid (SoL) biosynthetic enzymes to inflammatory bowel disease (IBD) in patients, revealing a negative correlation. This correlation is then corroborated by targeted metabolomics, identifying that SoLs abundance is significantly decreased in IBD patient samples. We experimentally validate our analysis in a mouse model of IBD, showing that SoLs production is indeed decreased while inflammatory markers are increased in diseased mice. In support of this connection, we apply bioactive molecular networking to show that SoLs consistently contribute to the immunoregulatory activity of SoL-producing human microbes. We further reveal that sulfobacins A and B, two representative SoLs, primarily target Toll-like receptor 4 (TLR4) to mediate immunomodulatory activity through blocking TLR4's natural ligand lipopolysaccharide (LPS) binding to myeloid differentiation factor 2, leading to significant suppression of LPS-induced inflammation and macrophage M1 polarization. Together, these results suggest that SoLs mediate a protective effect against IBD through TLR4 signaling and showcase a widely applicable biosynthetic enzyme-guided disease correlation approach to directly link the biosynthesis of gut microbial functional metabolites to human health.
栖息在人体肠道中的数万亿微生物与人类健康有着错综复杂的联系。在物种丰度水平上,相关性研究已将特定细菌分类群与各种疾病联系起来。虽然这些细菌在肠道中的丰度可作为疾病进展的良好指标,但了解它们产生的功能代谢产物对于解读这些微生物如何影响人类健康至关重要。在此,我们报告了一种独特的生物合成酶引导的疾病关联方法,以揭示微生物功能代谢产物作为人类健康中的潜在分子机制。我们直接将肠道微生物磺脂(SoL)生物合成酶的表达与患者的炎症性肠病(IBD)联系起来,发现呈负相关。然后通过靶向代谢组学证实了这种相关性,确定IBD患者样本中SoLs的丰度显著降低。我们在IBD小鼠模型中通过实验验证了我们的分析,表明患病小鼠中SoLs的产生确实减少而炎症标志物增加。为支持这种联系,我们应用生物活性分子网络来表明SoLs始终有助于产生SoL的人类微生物的免疫调节活性。我们进一步揭示,两种代表性的SoLs,即磺杆菌素A和B,主要靶向Toll样受体4(TLR4),通过阻断TLR4的天然配体脂多糖(LPS)与髓样分化因子2的结合来介导免疫调节活性,从而显著抑制LPS诱导的炎症和巨噬细胞M1极化。总之,这些结果表明SoLs通过TLR4信号传导介导对IBD的保护作用,并展示了一种广泛适用的生物合成酶引导的疾病关联方法,可直接将肠道微生物功能代谢产物的生物合成与人类健康联系起来。